Oral administration effects of β-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis
[Display omitted] To explore the effects of β-d-mannuronic acid (M2000) on levels of Th17, regulatory T (Treg) cells and their related cytokines in patients with ankylosing spondylitis (AS). 30 AS patients and 15 age and sex-matched healthy individuals were enrolled in this study. The frequencies of...
Gespeichert in:
| Veröffentlicht in: | Biomedicine & pharmacotherapy 2018-04, Vol.100, p.495-500 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 500 |
|---|---|
| container_issue | |
| container_start_page | 495 |
| container_title | Biomedicine & pharmacotherapy |
| container_volume | 100 |
| creator | Fattahi, Mohammad Javad Ahmadi, Hossein Jafarnezhad-Ansariha, Fahimeh Mortazavi-Jahromi, Seyed Shahabeddin Rehm, Bernd H.A. Cuzzocrea, Salvatore Matsuo, Hidenori Mirshafiey, Abbas |
| description | [Display omitted]
To explore the effects of β-d-mannuronic acid (M2000) on levels of Th17, regulatory T (Treg) cells and their related cytokines in patients with ankylosing spondylitis (AS).
30 AS patients and 15 age and sex-matched healthy individuals were enrolled in this study. The frequencies of Th17 and Treg cells and serum levels of related cytokines were measured by flow cytometry analysis and ELISA respectively, before (baseline) and 3 months after M2000 therapy.
Significantly higher baseline Th17 cells and serum IL-17, TNF-α and IL-6 were observed in AS patients than in normal controls, whereas baseline levels of Treg cells and serum IL-10 were not significantly different between AS patients and healthy controls. After M2000 therapy, frequencies of Th17 and serum levels of IL-17 and IL-6 significantly decreased in AS patients. The frequencies of Treg cells and serum level of IL-10 were not significantly changed, in comparison to before therapy. Moreover, the correlation analysis showed that frequencies of Th17 and levels of IL-17, TNF-α and IL-6 were positively correlated with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI) scores, whereas Treg cells were revealed to be negatively correlated with BASDAI and BASFI scores.
It can be concluded that the oral administration of M2000 as a novel NSAID with the immunosuppressive property that down-regulates Th17 and Th17-related cytokines and facilitates the correction of the Th17/Treg imbalance can be effective in the process of AS treatment. |
| doi_str_mv | 10.1016/j.biopha.2018.02.059 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2008363889</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332217366556</els_id><sourcerecordid>2008363889</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-edae7c936a43b6c55a9fd536faf23b67b159d8855c48c4b0304a3f2a9e5f82ed3</originalsourceid><addsrcrecordid>eNp9kM1u1DAQxy0EokvbN0DIx3JI8EecxBckVPElFfWynC3HHne9JHawk6K98kg8SJ8Jr7Zw7Gmk0W_-M_ND6DUlNSW0fbevBx_nna4ZoX1NWE2EfIY2VApStYR0z9GGdIJXnDN2hl7lvCeEiJb3L9EZk03XSco36Pdt0iPWdvLB5yXpxceAwTkwS8bR4Yc_la0mHcKaYvAGa-MtvvrGStZbXNDtjnZYB4sT3K2jXmI64C02MI4Z-4DnEgihRP3yy65wPw5jzD7c4TzHYA-jX3y-QC-cHjNcPtZz9P3Tx-31l-rm9vPX6w83leEtWyqwGjojeasbPrRGCC2dFbx12rHS6AYqpO17IUzTm2YgnDSaO6YlCNczsPwcXZ1y5xR_rpAXNfl8vFQHiGtW5aeeFz-9LGhzQk2KOSdwak5-0umgKFFH-2qvTvbV0b4iTBX7ZezN44Z1mMD-H_qnuwDvTwCUP-89JJVN8WPA-lSMKxv90xv-Ah4NmZ4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2008363889</pqid></control><display><type>article</type><title>Oral administration effects of β-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Fattahi, Mohammad Javad ; Ahmadi, Hossein ; Jafarnezhad-Ansariha, Fahimeh ; Mortazavi-Jahromi, Seyed Shahabeddin ; Rehm, Bernd H.A. ; Cuzzocrea, Salvatore ; Matsuo, Hidenori ; Mirshafiey, Abbas</creator><creatorcontrib>Fattahi, Mohammad Javad ; Ahmadi, Hossein ; Jafarnezhad-Ansariha, Fahimeh ; Mortazavi-Jahromi, Seyed Shahabeddin ; Rehm, Bernd H.A. ; Cuzzocrea, Salvatore ; Matsuo, Hidenori ; Mirshafiey, Abbas</creatorcontrib><description>[Display omitted]
To explore the effects of β-d-mannuronic acid (M2000) on levels of Th17, regulatory T (Treg) cells and their related cytokines in patients with ankylosing spondylitis (AS).
30 AS patients and 15 age and sex-matched healthy individuals were enrolled in this study. The frequencies of Th17 and Treg cells and serum levels of related cytokines were measured by flow cytometry analysis and ELISA respectively, before (baseline) and 3 months after M2000 therapy.
Significantly higher baseline Th17 cells and serum IL-17, TNF-α and IL-6 were observed in AS patients than in normal controls, whereas baseline levels of Treg cells and serum IL-10 were not significantly different between AS patients and healthy controls. After M2000 therapy, frequencies of Th17 and serum levels of IL-17 and IL-6 significantly decreased in AS patients. The frequencies of Treg cells and serum level of IL-10 were not significantly changed, in comparison to before therapy. Moreover, the correlation analysis showed that frequencies of Th17 and levels of IL-17, TNF-α and IL-6 were positively correlated with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI) scores, whereas Treg cells were revealed to be negatively correlated with BASDAI and BASFI scores.
It can be concluded that the oral administration of M2000 as a novel NSAID with the immunosuppressive property that down-regulates Th17 and Th17-related cytokines and facilitates the correction of the Th17/Treg imbalance can be effective in the process of AS treatment.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2018.02.059</identifier><identifier>PMID: 29477913</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Administration, Oral ; Adolescent ; Adult ; Ankylosing spondylitis ; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage ; Female ; Hexuronic Acids - administration & dosage ; Humans ; Immunosuppressive Agents - administration & dosage ; M2000 ; Male ; Mannuronic acid ; Middle Aged ; NSAID ; Spondylitis, Ankylosing - blood ; Spondylitis, Ankylosing - diagnosis ; Spondylitis, Ankylosing - drug therapy ; T-Lymphocytes, Regulatory - drug effects ; T-Lymphocytes, Regulatory - metabolism ; Th17 ; Th17 Cells - drug effects ; Th17 Cells - metabolism ; Treg ; Young Adult</subject><ispartof>Biomedicine & pharmacotherapy, 2018-04, Vol.100, p.495-500</ispartof><rights>2018 Elsevier Masson SAS</rights><rights>Copyright © 2018 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-edae7c936a43b6c55a9fd536faf23b67b159d8855c48c4b0304a3f2a9e5f82ed3</citedby><cites>FETCH-LOGICAL-c362t-edae7c936a43b6c55a9fd536faf23b67b159d8855c48c4b0304a3f2a9e5f82ed3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biopha.2018.02.059$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29477913$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fattahi, Mohammad Javad</creatorcontrib><creatorcontrib>Ahmadi, Hossein</creatorcontrib><creatorcontrib>Jafarnezhad-Ansariha, Fahimeh</creatorcontrib><creatorcontrib>Mortazavi-Jahromi, Seyed Shahabeddin</creatorcontrib><creatorcontrib>Rehm, Bernd H.A.</creatorcontrib><creatorcontrib>Cuzzocrea, Salvatore</creatorcontrib><creatorcontrib>Matsuo, Hidenori</creatorcontrib><creatorcontrib>Mirshafiey, Abbas</creatorcontrib><title>Oral administration effects of β-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis</title><title>Biomedicine & pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>[Display omitted]
To explore the effects of β-d-mannuronic acid (M2000) on levels of Th17, regulatory T (Treg) cells and their related cytokines in patients with ankylosing spondylitis (AS).
30 AS patients and 15 age and sex-matched healthy individuals were enrolled in this study. The frequencies of Th17 and Treg cells and serum levels of related cytokines were measured by flow cytometry analysis and ELISA respectively, before (baseline) and 3 months after M2000 therapy.
Significantly higher baseline Th17 cells and serum IL-17, TNF-α and IL-6 were observed in AS patients than in normal controls, whereas baseline levels of Treg cells and serum IL-10 were not significantly different between AS patients and healthy controls. After M2000 therapy, frequencies of Th17 and serum levels of IL-17 and IL-6 significantly decreased in AS patients. The frequencies of Treg cells and serum level of IL-10 were not significantly changed, in comparison to before therapy. Moreover, the correlation analysis showed that frequencies of Th17 and levels of IL-17, TNF-α and IL-6 were positively correlated with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI) scores, whereas Treg cells were revealed to be negatively correlated with BASDAI and BASFI scores.
It can be concluded that the oral administration of M2000 as a novel NSAID with the immunosuppressive property that down-regulates Th17 and Th17-related cytokines and facilitates the correction of the Th17/Treg imbalance can be effective in the process of AS treatment.</description><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Ankylosing spondylitis</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</subject><subject>Female</subject><subject>Hexuronic Acids - administration & dosage</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>M2000</subject><subject>Male</subject><subject>Mannuronic acid</subject><subject>Middle Aged</subject><subject>NSAID</subject><subject>Spondylitis, Ankylosing - blood</subject><subject>Spondylitis, Ankylosing - diagnosis</subject><subject>Spondylitis, Ankylosing - drug therapy</subject><subject>T-Lymphocytes, Regulatory - drug effects</subject><subject>T-Lymphocytes, Regulatory - metabolism</subject><subject>Th17</subject><subject>Th17 Cells - drug effects</subject><subject>Th17 Cells - metabolism</subject><subject>Treg</subject><subject>Young Adult</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1u1DAQxy0EokvbN0DIx3JI8EecxBckVPElFfWynC3HHne9JHawk6K98kg8SJ8Jr7Zw7Gmk0W_-M_ND6DUlNSW0fbevBx_nna4ZoX1NWE2EfIY2VApStYR0z9GGdIJXnDN2hl7lvCeEiJb3L9EZk03XSco36Pdt0iPWdvLB5yXpxceAwTkwS8bR4Yc_la0mHcKaYvAGa-MtvvrGStZbXNDtjnZYB4sT3K2jXmI64C02MI4Z-4DnEgihRP3yy65wPw5jzD7c4TzHYA-jX3y-QC-cHjNcPtZz9P3Tx-31l-rm9vPX6w83leEtWyqwGjojeasbPrRGCC2dFbx12rHS6AYqpO17IUzTm2YgnDSaO6YlCNczsPwcXZ1y5xR_rpAXNfl8vFQHiGtW5aeeFz-9LGhzQk2KOSdwak5-0umgKFFH-2qvTvbV0b4iTBX7ZezN44Z1mMD-H_qnuwDvTwCUP-89JJVN8WPA-lSMKxv90xv-Ah4NmZ4</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Fattahi, Mohammad Javad</creator><creator>Ahmadi, Hossein</creator><creator>Jafarnezhad-Ansariha, Fahimeh</creator><creator>Mortazavi-Jahromi, Seyed Shahabeddin</creator><creator>Rehm, Bernd H.A.</creator><creator>Cuzzocrea, Salvatore</creator><creator>Matsuo, Hidenori</creator><creator>Mirshafiey, Abbas</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201804</creationdate><title>Oral administration effects of β-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis</title><author>Fattahi, Mohammad Javad ; Ahmadi, Hossein ; Jafarnezhad-Ansariha, Fahimeh ; Mortazavi-Jahromi, Seyed Shahabeddin ; Rehm, Bernd H.A. ; Cuzzocrea, Salvatore ; Matsuo, Hidenori ; Mirshafiey, Abbas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-edae7c936a43b6c55a9fd536faf23b67b159d8855c48c4b0304a3f2a9e5f82ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Ankylosing spondylitis</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</topic><topic>Female</topic><topic>Hexuronic Acids - administration & dosage</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>M2000</topic><topic>Male</topic><topic>Mannuronic acid</topic><topic>Middle Aged</topic><topic>NSAID</topic><topic>Spondylitis, Ankylosing - blood</topic><topic>Spondylitis, Ankylosing - diagnosis</topic><topic>Spondylitis, Ankylosing - drug therapy</topic><topic>T-Lymphocytes, Regulatory - drug effects</topic><topic>T-Lymphocytes, Regulatory - metabolism</topic><topic>Th17</topic><topic>Th17 Cells - drug effects</topic><topic>Th17 Cells - metabolism</topic><topic>Treg</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fattahi, Mohammad Javad</creatorcontrib><creatorcontrib>Ahmadi, Hossein</creatorcontrib><creatorcontrib>Jafarnezhad-Ansariha, Fahimeh</creatorcontrib><creatorcontrib>Mortazavi-Jahromi, Seyed Shahabeddin</creatorcontrib><creatorcontrib>Rehm, Bernd H.A.</creatorcontrib><creatorcontrib>Cuzzocrea, Salvatore</creatorcontrib><creatorcontrib>Matsuo, Hidenori</creatorcontrib><creatorcontrib>Mirshafiey, Abbas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine & pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fattahi, Mohammad Javad</au><au>Ahmadi, Hossein</au><au>Jafarnezhad-Ansariha, Fahimeh</au><au>Mortazavi-Jahromi, Seyed Shahabeddin</au><au>Rehm, Bernd H.A.</au><au>Cuzzocrea, Salvatore</au><au>Matsuo, Hidenori</au><au>Mirshafiey, Abbas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral administration effects of β-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis</atitle><jtitle>Biomedicine & pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2018-04</date><risdate>2018</risdate><volume>100</volume><spage>495</spage><epage>500</epage><pages>495-500</pages><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>[Display omitted]
To explore the effects of β-d-mannuronic acid (M2000) on levels of Th17, regulatory T (Treg) cells and their related cytokines in patients with ankylosing spondylitis (AS).
30 AS patients and 15 age and sex-matched healthy individuals were enrolled in this study. The frequencies of Th17 and Treg cells and serum levels of related cytokines were measured by flow cytometry analysis and ELISA respectively, before (baseline) and 3 months after M2000 therapy.
Significantly higher baseline Th17 cells and serum IL-17, TNF-α and IL-6 were observed in AS patients than in normal controls, whereas baseline levels of Treg cells and serum IL-10 were not significantly different between AS patients and healthy controls. After M2000 therapy, frequencies of Th17 and serum levels of IL-17 and IL-6 significantly decreased in AS patients. The frequencies of Treg cells and serum level of IL-10 were not significantly changed, in comparison to before therapy. Moreover, the correlation analysis showed that frequencies of Th17 and levels of IL-17, TNF-α and IL-6 were positively correlated with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI) scores, whereas Treg cells were revealed to be negatively correlated with BASDAI and BASFI scores.
It can be concluded that the oral administration of M2000 as a novel NSAID with the immunosuppressive property that down-regulates Th17 and Th17-related cytokines and facilitates the correction of the Th17/Treg imbalance can be effective in the process of AS treatment.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>29477913</pmid><doi>10.1016/j.biopha.2018.02.059</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0753-3322 |
| ispartof | Biomedicine & pharmacotherapy, 2018-04, Vol.100, p.495-500 |
| issn | 0753-3322 1950-6007 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2008363889 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Administration, Oral Adolescent Adult Ankylosing spondylitis Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Female Hexuronic Acids - administration & dosage Humans Immunosuppressive Agents - administration & dosage M2000 Male Mannuronic acid Middle Aged NSAID Spondylitis, Ankylosing - blood Spondylitis, Ankylosing - diagnosis Spondylitis, Ankylosing - drug therapy T-Lymphocytes, Regulatory - drug effects T-Lymphocytes, Regulatory - metabolism Th17 Th17 Cells - drug effects Th17 Cells - metabolism Treg Young Adult |
| title | Oral administration effects of β-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T12%3A31%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20administration%20effects%20of%20%CE%B2-d-mannuronic%20acid%20(M2000)%20on%20Th17%20and%20regulatory%20T%20cells%20in%20patients%20with%20ankylosing%20spondylitis&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Fattahi,%20Mohammad%20Javad&rft.date=2018-04&rft.volume=100&rft.spage=495&rft.epage=500&rft.pages=495-500&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2018.02.059&rft_dat=%3Cproquest_cross%3E2008363889%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2008363889&rft_id=info:pmid/29477913&rft_els_id=S0753332217366556&rfr_iscdi=true |